Boston, MA, May 12, 2025 – General Oncology, Inc., a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class treatments for metastatic cancers, today announced that members of its senior management team will participate in three upcoming conferences in May and June 2025:
Pharma Partnering US Summit
Company Presentation: Abid Ansari (CFO)
Date and Time: Thursday, May 15, 11:00 – 11:20 a.m. PT
American Society of Clinical Oncology (ASCO)
Booth 24156: Jeff Glazier (CEO), Abid Ansari (CFO), and Dr. Arny Glazier (CSO)
Date: May 30 – June 3
BIO International Convention
Booth 3578: Jeff Glazier (CEO) and Abid Ansari (CFO)
Date: June 16-19
About General Oncology, Inc.
General Oncology is a clinical-stage biopharmaceutical company dedicated to pioneering first-in-class medicines for metastatic cancers. The company is developing GO-4, an investigational therapy for metastatic cancers, currently completing the phase 1 SHARON trial (NCT04150042) for metastatic cancers in the setting of a BRCA1/2 or PALB2 mutation. With a commitment to innovation, General Oncology is focused on advancing transformative therapies for cancer patients. For more information about General Oncology, please visit www.generaloncology.com.
Investor Contact:
- Abid Ansari
- (617) 468-4646
- ir@generaloncology.com
Media Contact:
- Madelin Hawtin
- mhawtin@lifescicomms.com